Kineta Finds New Funding

Seattle-based Kineta, the biopharmaceuticals firm developing treatments for infection and autoimmune diseases, said yesterday that it has scored a new investment from RLB Holdings, the investment group which also owns the New York Yankees. According to Kineta, RLB Holdings has made a second investment in the firm, which will help it manufacture a drug lot for its forthcoming clinical trials. Kineta's lead compound is a host-directed antiviral focused on influenza, West Nile virus, Dengue fever, and other contagious diseases. Size of the latest funding round was not announced, however, Kineta said it has now raised more than $40M in funding since it launched in 2008. More information »